Oda Studio vs Uncommon Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Oda Studio leads in AI visibility (40 vs 27)

Oda Studio

EmergingReal Estate & Property Tech

General

US YC W20 AI interior design platform with style preference discovery and room visualization; generating personalized moodboards and shoppable décor matches competing with Houzz for AI-native home design discovery.

AI VisibilityBeta
Overall Score
C40
Category Rank
#468 of 1167
AI Consensus
64%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
44
Gemini
45

About

Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal design aesthetic, visualize how spaces would look with different furniture and décor, and find matching products from online retailers. Users select style preferences (mid-century modern, bohemian, minimalist, coastal) and color palettes (navy, salmon, olive, beige) and receive AI-generated moodboards and room transformation visuals in seconds — with the platform linking out to purchasable products that match the visualized design. Founded in 2020 and enhanced with more sophisticated AI algorithms in 2024-2025, Oda Studio serves the design discovery and product-matching need that exists in the early stages of home decorating before interior designers are typically engaged.

Full profile

Uncommon Therapeutics

EmergingHealthcare

General

Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.

AI VisibilityBeta
Overall Score
D27
Category Rank
#1121 of 1167
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
33
Gemini
36

About

Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.

Full profile

AI Visibility Head-to-Head

40
Overall Score
27
#468
Category Rank
#1121
64
AI Consensus
67
stable
Trend
stable
34
ChatGPT
28
44
Perplexity
33
45
Gemini
36
33
Claude
22
34
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.